CVS Health Corp vs Dover Corp — how do they compare? CVS Health Corp trades at $86.76 (market cap $112.29B), while Dover Corp trades at $188.77 (market cap $25.45B). The key difference: CVS Health Corp is far larger — about 4.4× Dover Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Dover Corp for 73 Days on average.
| CVS | DOV | |
|---|---|---|
Market Cap | $112.29B | $25.45B |
Volume | 7,763,676 | 661,758 |
Sector | Health | Industrials |
52-Week High | $110.60 | $233.31 |
52-Week Low | $70.08 | $161.16 |
Typical Hold Time | 83 Days | 73 Days |
Enterprise Value | $174.64B | $26.95B |
Dividend Yield | 3.03% | 1.11% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
Dover Corporation (DOV) trades at $188.29, down 1.87% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and healthy profitability (13.48% net margin, 14.98% ROE). Recent acquisitions of Cloeren and Leistung expand manufacturing capabilities, while analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The outlook remains positive given Dover's Dividend King status, strategic acquisitions, and Wall Street support. Key risks include cyclical industrial exposure and recent negative cash flow trends. With no analyst sell ratings and technical indicators suggesting potential oversold conditions, the stock presents a compelling opportunity for long-term investors despite near-term bearish technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →